Clinical studies to elucidate the molecular mechanisms associated with the pathogenesis of amyotrophic lateral sclerosis (ALS) and to identify effective drug targets
Not Applicable
Recruiting
- Conditions
- Amyotrophic lateral sclerosis
- Registration Number
- JPRN-UMIN000051823
- Lead Sponsor
- Keio University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
The case when the subject does not agree to participate in this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are being investigated in JPRN-UMIN000051823 for ALS pathogenesis and drug target identification?
How does Keio University's observational study compare novel therapeutic targets to standard-of-care treatments for ALS?
Which biomarkers are prioritized in JPRN-UMIN000051823 for stratifying ALS patients and predicting treatment response?
What adverse events are associated with experimental drug targets in ALS research at Keio University's clinical study?
How do SOD1, C9ORF72, or TDP-43-related mechanisms in JPRN-UMIN000051823 align with emerging ALS therapies like antisense oligonucleotides?